These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 26818835)

  • 1. Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma.
    Laurinavicius A; Plancoulaine B; Rasmusson A; Besusparis J; Augulis R; Meskauskas R; Herlin P; Laurinaviciene A; Abdelhadi Muftah AA; Miligy I; Aleskandarany M; Rakha EA; Green AR; Ellis IO
    Virchows Arch; 2016 Apr; 468(4):493-502. PubMed ID: 26818835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer.
    Besusparis J; Plancoulaine B; Rasmusson A; Augulis R; Green AR; Ellis IO; Laurinaviciene A; Herlin P; Laurinavicius A
    Diagn Pathol; 2016 Aug; 11(1):82. PubMed ID: 27576949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A methodology for comprehensive breast cancer Ki67 labeling index with intra-tumor heterogeneity appraisal based on hexagonal tiling of digital image analysis data.
    Plancoulaine B; Laurinaviciene A; Herlin P; Besusparis J; Meskauskas R; Baltrusaityte I; Iqbal Y; Laurinavicius A
    Virchows Arch; 2015 Oct; ():. PubMed ID: 26481244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma.
    Zilenaite D; Rasmusson A; Augulis R; Besusparis J; Laurinaviciene A; Plancoulaine B; Ostapenko V; Laurinavicius A
    Front Oncol; 2020; 10():950. PubMed ID: 32612954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma.
    Laurinavicius A; Green AR; Laurinaviciene A; Smailyte G; Ostapenko V; Meskauskas R; Ellis IO
    Oncotarget; 2015 Dec; 6(38):41134-45. PubMed ID: 26512778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral heterogeneity of Ki67 proliferation index outperforms conventional immunohistochemistry prognostic factors in estrogen receptor-positive HER2-negative breast cancer.
    Zilenaite-Petrulaitiene D; Rasmusson A; Besusparis J; Valkiuniene RB; Augulis R; Laurinaviciene A; Plancoulaine B; Petkevicius L; Laurinavicius A
    Virchows Arch; 2024 Jan; ():. PubMed ID: 38217716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue.
    Laurinavicius A; Plancoulaine B; Laurinaviciene A; Herlin P; Meskauskas R; Baltrusaityte I; Besusparis J; Dasevicius D; Elie N; Iqbal Y; Bor C
    Breast Cancer Res; 2014; 16(2):R35. PubMed ID: 24708745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement.
    Koopman T; Buikema HJ; Hollema H; de Bock GH; van der Vegt B
    Breast Cancer Res Treat; 2018 May; 169(1):33-42. PubMed ID: 29349710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score.
    Robertson S; Acs B; Lippert M; Hartman J
    Breast Cancer Res Treat; 2020 Aug; 183(1):161-175. PubMed ID: 32572716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients.
    Radziuviene G; Rasmusson A; Augulis R; Grineviciute RB; Zilenaite D; Laurinaviciene A; Ostapenko V; Laurinavicius A
    Front Oncol; 2021; 11():774088. PubMed ID: 34858854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancer.
    Gudlaugsson E; Klos J; Skaland I; Janssen EA; Smaaland R; Feng W; Shao Z; Malpica A; Baak JP
    Pol J Pathol; 2013 Apr; 64(1):1-8. PubMed ID: 23625593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer.
    Stålhammar G; Robertson S; Wedlund L; Lippert M; Rantalainen M; Bergh J; Hartman J
    Histopathology; 2018 May; 72(6):974-989. PubMed ID: 29220095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.
    Bertucci F; Finetti P; Roche H; Le Doussal JM; Marisa L; Martin AL; Lacroix-Triki M; Blanc-Fournier C; Jacquemier J; Peyro-Saint-Paul H; Viens P; Sotiriou C; Birnbaum D; Penault-Llorca F
    Ann Oncol; 2013 Mar; 24(3):625-32. PubMed ID: 23117074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer.
    Şahin S; Işık Gönül İ; Çakır A; Seçkin S; Uluoğlu Ö
    Int J Surg Pathol; 2016 Oct; 24(7):607-13. PubMed ID: 27284123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.
    Niikura N; Masuda S; Kumaki N; Xiaoyan T; Terada M; Terao M; Iwamoto T; Oshitanai R; Morioka T; Tuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
    Clin Breast Cancer; 2014 Oct; 14(5):323-329.e3. PubMed ID: 24492237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.
    Joshi S; Watkins J; Gazinska P; Brown JP; Gillett CE; Grigoriadis A; Pinder SE
    BMC Cancer; 2015 Jul; 15():546. PubMed ID: 26205655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive lobular carcinoma of the breast: assessment of proliferative activity using automated Ki-67 immunostaining.
    Dessauvagie B; Thomas A; Thomas C; Robinson C; Combrink M; Budhavaram V; Kunjuraman B; Meehan K; Sterrett G; Harvey J
    Pathology; 2019 Dec; 51(7):681-687. PubMed ID: 31630876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data.
    Laurinavicius A; Laurinaviciene A; Ostapenko V; Dasevicius D; Jarmalaite S; Lazutka J
    Diagn Pathol; 2012 Mar; 7():27. PubMed ID: 22424533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses' Health Study.
    Healey MA; Hirko KA; Beck AH; Collins LC; Schnitt SJ; Eliassen AH; Holmes MD; Tamimi RM; Hazra A
    Breast Cancer Res Treat; 2017 Nov; 166(2):613-622. PubMed ID: 28791482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.